Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Yum! Brands, Inc. (YUM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Yum! Brands, Inc. — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $281.81 (market cap $39.89B), while Yum! Brands, Inc. trades at $163.42 (market cap $45.08B). The key difference: Alnylam Pharmaceuticals, Inc. and Yum! Brands, Inc. are close in size by market cap, and Yum! Brands, Inc. pays a 1.83% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | YUM | |
|---|---|---|
Market Cap | $39.89B | $45.08B |
Sector | Health | Consumer Cyclical |
52-Week High | $491.22 | $168.16 |
52-Week Low | $278.09 | $138.21 |
Enterprise Value | $38.15B | $56.34B |
Dividend Yield | — | 1.83% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
YUM trades at $163.54, up 0.71% with bullish technical signals and strong support at $158. Revenue grew to $8.21B in 2025 with a 20.48% net margin, though profit margins have slightly declined. The recent $2.7B Pizza Hut sale and $4B buyback authorization highlight strategic focus on KFC and Taco Bell growth. Cash flow from operations remains robust at $2.01B, supporting dividend payments and debt management.
Outlook is positive with analyst consensus target of $174 offering 6.4% upside, but high debt levels and competitive pressures pose risks. The stock's valuation at 26.38 P/E requires sustained earnings growth to justify further gains, making execution on digital initiatives and international expansion critical near-term catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Yum! Brands, Inc.
Yum Brands is a U.S.-based restaurant operator featuring a portfolio of four brands: KFC (26,930 global units), Pizza Hut (18,380 units), Taco Bell (7,790 units), and The Habit Burger (310 units) at year-end 2021. With $58 billion in 2021 systemwide sales, the firm is the second-largest restaurant company in the world, behind McDonald's ($112.5 billion) but ahead of Restaurant Brands International ($36 billion) and Starbucks ($25 billion). Yum is 98% franchised, with the largest franchisee, Yum China, created via a 2016 spinoff transaction (after which Yum China agreed to pay 3% royalties to Yum Brands in perpetuity). Yum is the newest evolution of Tricon Brands, formerly a division of PepsiCo, and generates the bulk of its revenue from franchise royalties and marketing contributions.
Read more on YUM →
